2023年某三甲医院抗肿瘤相关药物医嘱合理使用情况分析OA

Objective To analyze the rationality of clinical use of antitumor related drugs,and to provide reference for regu-lating physicians'prescribing behavior and promoting rational drug use.Methods In 2023,90 medical records of hospital-ized patients using antitumor drugs in Yiyang Central Hospital were selected every quarter,and a total of 360 medical records were reviewed to analyze and evaluate their use.Results There were irrational use of antitumor drugs and their aux-iliary drugs.Patients over 50 years old accounted for 72.12％of the unreasonable medical orders,and the departments were mainly distributed in the First Tumor Area,the Second Tumor Area and the Third General Surgery Department,accounting for 73.08％.According to the distribution of drug varieties,the top four irrational rates were Palonosetron(27.92％),Doc-etaxel(17.53％),Paclitaxel(albumin-bound)(11.04％)and Foxapitant(7.79％).The existing problems mainly include five aspects:inappropriate pretreatment,inappropriate usage and dosage,inappropriate route of administration,inappropriate anti-vomiting intensity and inappropriate solvent volume.Through the combination of real-time intervention by clinical pharmacists and medical quality evaluation,the unreasonable rate of medical orders(based on medical records)decreased from 35.56％in 2022 to 28.89％in 2023.Conclusion The deficiencies of clinical drug use can be found through the review of medical orders,and timely intervention measures can improve the level of clinical rational drug use.